Spots Global Cancer Trial Database for Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Official Title: A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Study ID: NCT01767766
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
TG Therapeutics Trial Site, Sarasota, Florida, United States
TG Therapeutics Trial Site, Hackensack, New Jersey, United States
TG Therapeutics Trial Site, New York, New York, United States
TG Therapeutics Trial Site, Durham, North Carolina, United States
TG Therapeutics Trial Site, Cincinnati, Ohio, United States
TG Therapeutics Trial Site, Nashville, Tennessee, United States
TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States
Contact Details
Name: Howard Burris, MD, FACP
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
